Southern Railway Paramedical Recruitment 2020: Southern Railway has invited applications for recruitment to the post of Intensivsts, Diagnostic, Physician and GDMO for a period up to 31.12.2020 from the date of engagement to manage the COVID-19 wards at Railway Hospital/Perambur, Chennai. Interested candidates can apply to the posts on or before 6 October 2020.
Important Dates:
- Last date for submission of online application: 6 October 2020
Southern Railway Paramedical Recruitment 2020 Vacancy Details
- Intensivists - 8 Posts
- Diagnostic Radiologists - 4 Posts
- Physician - 6 Posts
- GDMO - 14 Posts
Southern Railway Paramedical Recruitment 2020 Eligibility Criteria
Educational Qualification:
- Intensivists - MD in Internal Medicine/Anaethesia/Pulmonary Medicine/Emergency Medicine. Fellowship in Intensive care or at least one year in ICU of a reputed hospital.
- Diagnostic Radiologists - MD/DNB in Radio Diagnostic with 3 years experience in all modalities.
- Physician - MD in Internal Medicine / Pulmonary Medicine work experience of one year in a reputed hospital.
- GDMO - M.B.B.S with experience in ICU working and operation of ventilator Machine or The candidate should be M.B.B.S and registered with the Indian Medical Council.
Southern Railway Paramedical Recruitment 2020 Salary - Rs. 75,000/-(GDMO), Rs. 95,000/- (Specialists)
Southern Railway Paramedical Recruitment 2020 Age Limit - must not attain 53 years. However, this upper age limit is relaxable up to 5 years for SC/ST and 3 years for OBC candidates.
Download Southern Railway Paramedical Recruitment 2020 Notification Here
How to apply for Southern Railway Paramedical Recruitment 2020
Interested candidates can apply to the posts by sending applications along with the documents to covid19cmp20@gmail.com on or before 6 November 2020 till 6 PM.
Also Check Latest Government Jobs:
NHM Bihar Recruitment 2020, Apply 122 Hospital Manager & Other Posts @ statehealthsocietybihar.org
DRDO DFRL Apprentice Notification 2020: 15 Vacancies Notified, Walk-In
Comments
All Comments (0)
Join the conversation